Regeneron to Present Pivotal Phase 3 FOP Data, Other Pipeline Updates at Upcoming Medical Conferences
Summary
Regeneron announced it will present new clinical data and research at the American Diabetes Association (ADA) and Endocrine Society (ENDO) annual meetings in June. The most significant presentation will be pivotal Phase 3 efficacy and safety data for garetosmab in fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. The company will also share Phase 2 data for trevogrumab in obesity and early preclinical data for Graves' and thyroid eye disease. This follows a strong period of pipeline advancements and approvals for Regeneron. The actual data presentations at ADA (June 5-8) and ENDO (June 13-16) will be key events for investors.
At the time of this announcement, REGN was trading at $600.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $64.9B. The 52-week trading range was $476.49 to $821.11. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.